Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

Inclusion Criteria: * Women, 25 to 50 years old. * Cervical HSIL diagnosis made within 2 months of enrollment and confirmed with biopsy with no evidence of invasive cancer in any specimen and must be p16+. * Able and willing to abstain from sexual intercourse for 48 hours prior to first dose and 2 days after each dose. * Generally experiencing regular menstrual cycles, unless using long-acting reversible contraception that induces amenorrhea (e.g., Mirena IUD, Norplant). Exclusion Criteria: * Women who are pregnant, plan to become pregnant in the next 4 months, or lactating females. * History of cancer, except basal cell or squamous cell carcinoma of the skin. * History of genital herpes with \> 3 outbreaks per year, or active non-HPV vaginal infection. * Plan to have excision or ablation of the lesion(s) within 3 months of enrollment. * History of cervical cancer, colposcopy suspicious for cancer, any prior treatment of CIN, or hysterectomy.